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Characteristics of Patients Experiencing Extrapyramidal
Symptoms or Other Movement Disorders Related to
Dopamine Receptor Blocking Agent Therapy
Shaina Musco, PharmD,*†‡ Laura Ruekert, PharmD, BCPP, BCGP,†‡ Jaclyn Myers, PharmD,§||
Dennis Anderson, MD,¶ Michael Welling, MD,¶ and Elizabeth Ann Cunningham, DO¶
Abstract:
Purpose/Background: Dopamine receptor blocking agents (DRBAs),
also known as antipsychotics, are medications widely used to treat a grow-
ing number of mental health diagnoses. However, their utility is limited by
the potential to cause serious adverse movement reactions. Akathisia, dys-
tonia, parkinsonism, and tardive dyskinesia (collectively known as extrapy-
ramidal symptoms or EPSs) are associated with reduced social and occupational
functioning, negative patient attitudes toward treatment, and nonadherence
to pharmacotherapy. Neuroleptic malignant syndrome is a life-threatening
reaction that can result from DRBA use and cause musculoskeletal dys-
function. The aim of this study is to profile patients who have developed
DRBA-related movement adverse effects and identify risk factors signifi-
cantly associated with each subtype of EPSs or other movement disorders
(OMDs) such as neuroleptic malignant syndrome.
Methods/Procedures: A report of all potential DRBA-related EPSs or
OMDs occurrences within a large community hospital network was gener-
ated using International Classification of Diseases, Ninth Revision (ICD-9)
and 10th Revision (ICD-10) billing codes. Each patient encounter was
manually reviewed to confirm that a documented case of DRBA-related
EPSs or OMDs had indeed occurred and subsequently determine the likely
causative agent(s).
Findings/Results: The resultant cohort of 148 patients experiencing unique
DRBA-related EPS or OMD events was analyzed. The average patient was
female, middle-aged, and overweight. The most common DRBAs precipi-
tating EPSs or OMDs were haloperidol and quetiapine. In the population
studied, age was significantly associated with the subtype of EPSs experi-
enced such that those patients with akathisia and dystonia tended to be
younger, whereas those with tardive dyskinesia tended to be older. Body
mass index (BMI) category was also negatively correlated with the inci-
dence of dystonia. In addition, it was observed that exposure to specific
DRBAs, classes, and routes of administration significantly affected the risk
of developing different subtypes of EPSs orOMDs in the study population.
Implications/Conclusions: To our knowledge, this is the first study to
describe an association between age and BMI with the risk of akathisia and
dystonia, respectively, in patients taking DRBAs. Other trends observed
with age and BMI in patients developing DRBA-related EPSs support pre-
viously reported findings. Expanding the knowledge base of individual
characteristics associatedwith the risk of developing different subtypes of EPSs
or OMDs can help providers and patients anticipate and attempt to mitigate
these reactions, and may ultimately improve adherence to DRBA therapy.
Key Words: dopamine receptor blocking agent, antipsychotic,
extrapyramidal symptom, age, body mass index
(J Clin Psychopharmacol 2019;39: 336–343)
D opamine receptor blocking agents (DRBAs) are a dynamicclass of medications initially developed to reduce psychotic
symptoms in patients suffering from schizophrenia. Since that time,
their use has greatly expanded, and DRBAs are now used to treat a
variety of psychiatric conditions including major depressive
disorder, bipolar disorder, and irritability associated with autis-
tic disorder. The importance of DRBA treatment in patients
with first-break psychosis1 and major depressive disorder not
responding to first-line antidepressant monotherapy2 has recently
been demonstrated in terms of reduced hospital admissions and
health care costs. Early initiation of long-acting injectable DRBA
formulations has also garnered significant value by decreasing
hospitalizations and overall costs within contemporary interna-
tional practice models.3,4
The efficacy and versatility of DRBAs have led them to be-
comewidely used. However, the rate of nonadherence is high in pa-
tients to whom these medications are prescribed.5,6 A landmark
prospective randomized cohort study of patients with chronic
schizophrenia found that 74% had stopped taking their DRBA
within 18 months of the original prescription date.7 Outcomes
can be extremely poor for these patients, and medication nonad-
herence in the psychiatric population has been found to correlate
with increased hospital admissions, suicide, and mortality.8,9
A significant contributing factor to DRBA nonadherence is
lack of tolerability.10–12 This class of medications carries the risk
of causing a unique constellation of adverse effects called extrapy-
ramidal symptoms (EPSs), which are exhibited by abnormal move-
ments and/or muscle tone. The physical manifestations of EPSs can
range from pacing to paralysis and can have a substantial adverse
impact on patients' overall health and well-being.13–15 Cases of
EPSs have even resulted in medical malpractice16 owing to the se-
verity of symptoms experienced.
Extrapyramidal symptoms have been linked to increased like-
lihood of DRBA treatment discontinuation.17–20 Physical manifes-
tations such as tremor, bradykinesia, and rigidity can impair social
and occupational functioning.18 Psychological symptoms of EPSs
such as dysphoria, apathy, and cognitive impairment are major con-
tributors to negative patient and caregiver attitudes toward DRBA
therapy.18 Extrapyramidal symptoms have direct adverse effects
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on cognitive function as well.20 Dopamine receptor blocking
agents with high anticholinergic burden or requiring the use of ad-
junctive anticholinergic agents to treat EPSs can impair cognitive
processes such as learning and memory.18
Extrapyramidal symptoms negatively impact overall outcomes
related to efficacy, functioning, caregiver burden, and quality of
life.18 This is especially critical in a patient population that may al-
ready be at high risk for poor outcomes owing to issues with moti-
vation and beliefs about treatment. Patients prescribed DRBAs tend
to harbor unfavorable attitudes toward treatment and perceive EPSs
to be more severe than other adverse effects such as weight gain.21
Akathisia is a particularly distressing form of EPS and has
been implicated in many negative outcomes, including worsening
psychotic symptoms, increased suicidality, nonadherence to
DRBA therapy, and subsequent relapse.18,22 Akathisia can
manifest as anxiety and often go undiagnosed or mistaken for
agitation.16,22 Tardive dyskinesia (TD), a type of DRBA-related
movement disorder that can lead to serious physical impairment,
is associated with stigma, decline in social functioning, and in-
creased mortality.18 Orofacial movements associated with TD
have been linked to workplace discrimination23 and increased
mortality owing to respiratory infections.24 These secondary con-
sequences attributable to EPSs or OMDs can be severe enough to
offset any benefit from reduction in positive symptoms garnered
by the use of a DRBA.18
Neuroleptic malignant syndrome (NMS) is an adverse reac-
tion to DRBAs not classified as a type of EPSs, but similarly char-
acterized by abnormal movements and the potential for serious
sequelae. Hereafter, NMSwill be referred to as an other movement
disorder or OMD. Patients with NMS can present with muscle ri-
gidity, tremor, abnormal reflexes, and seizures.25 Considerablemor-
bidity is associated with NMS, including medical complications
such as rhabdomyolysis, acute respiratory failure, acute kidney in-
jury, and sepsis.26 Furthermore, NMS continues to carry risk for
mortality despite advances in treatment,26 making recognition
and avoidance of this adverse reaction critical.
Based on what is known about the severity of EPSs or OMDs
and the overall burden of these adverse effects to patients taking
DRBAmedications, it is vital to understand risk factors associated
with their development. Existing literature provides some clues as
to which patient may be at greater risk for experiencing these out-
comes and potential strategies to mitigate that risk. For example,
patients with first episode psychosis are more sensitive to devel-
oping EPSs from DRBAs,27 and new users of DRBAs have a sig-
nificantly greater risk of EPSs than chronic users, independent of
agent, diagnosis, or treatment setting.28 As a result, it is especially
important to start at low doses of DRBAs and taper up slowly in
treatment naive individuals to avoid development of EPSs. Certain
other patient populations takingDRBAsmay be at an increased risk
for such effects based on predisposing baseline characteristics.
There is a paucity of data to guide the use of DRBAs to re-
duce the risk of adverse movement reactions such as EPSs or
OMDs. Nonadherence due to poor tolerability can result in nega-
tive patient outcomes, including excess mortality. Patients taking
DRBAs may be at an increased risk for certain subtypes of EPSs
or OMDs based on predisposing individual characteristics. If
known, steps may be taken to identify and mitigate these risks
early in an effort to improve the likelihood of treatment success.
The primary objective of the present study is to determine if a sta-
tistically significant relationship exists between subtype of EPSs
or OMDs experienced by patients taking DRBAs and each of
the following patient characteristics: age, sex, body mass index
(BMI) category, DRBA name, DRBA classification, DRBA route
of administration, number of DRBAs prescribed, daily chlorprom-
azine equivalents, and the presence of DRBA overdose.
MATERIALS AND METHODS
A report of all potential DRBA-related EPSs or OMDs occur-
rences over a 5-year period was generated using International Clas-
sification of Diseases, Ninth Revision (ICD-9) and 10th Revision
(ICD-10), billing codes (see Supplementary Appendix 1, Supple-
mental Digital Content 1, http://links.lww.com/JCP/A579, for com-
plete list). The study was conducted at a large community hospital
network that serves a primarily suburban population in the Mid-
western United States and includes a 120-bed inpatient psychiatric
facility. This study was approved by the local institutional review
board on September 19, 2017, after qualifying for expedited review.
Patients of any age or sexwith an encounter between September
17, 2012, and November 1, 2017, at a site within the health system
using Epic Hyperspace 2015 electronic medical records were in-
cluded. Vulnerable populations (pregnant, incarcerated, or fetuses)
were excluded. Each resultant patient encounter was manually re-
viewed and vetted for accuracy by author S.M. and acknowledged
research assistants to ensure that the documented reaction was in-
deed EPS or OMD and that the patient had taken a DRBA imme-
diately before or during the encounter. For single encounters in
which a patient exhibited symptoms of multiple subtypes of EPSs
or OMDs, each was counted as an individual occurrence for that
subtype of EPSs or OMDs (n = 12). In addition, the same patient
could be counted multiple times for the same subtype of EPSs or
OMDs if it occurred in unique encounters (n = 12).
Daily chlorpromazine equivalents were calculated using pub-
lished conversion rates.29 The dose ranges used for analysis corre-
spond to lowor acute dosing (<200mg), averagemaintenance therapy
dosing for schizophrenia (200–1000 mg), and supratherapeutic dosing
FIGURE 1. Patient selection process. There were over 30,000
eligible unique patient encounters in which DRBA was
administered during the 5-year study period. A total of 391 were
billed for using ICD codes indicative of DRBA-related EPSs or
OMDs. After manual chart review was completed, 148 encounters
were verified as having DRBA-related EPSs or OMDs. Of the 243
encounters not verified, 77 had no clear adverse drug reaction,
98 had a non-DRBA–related adverse drug reaction, and 65 had a
DRBA-related adverse drug reaction that was not EPS or OMD.
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(>1000 mg) and are based on values reported in the literature.30,31
The Anticholinergic Cognitive Burden (ACB) scale was used to
quantify the anticholinergic properties of each DRBA examined,
where 0 denoted no known properties, 1 denoted possible anticho-
linergic, and 2 or 3 denoted definite anticholinergic.32
Descriptive statistics were used to analyze patient characteristics
including age, sex, BMI category, DRBA name, DRBA classifica-
tion, DRBA route of administration, number of DRBAs prescribed,
daily chlorpromazine equivalents, and the presence of DRBA over-
dose. Dopamine receptor blocking agent overdose in this study was
defined as the intentional or unintentional exposure to a dose of a
given agent that exceeded the prescribed dose. Dopamine receptor
blocking agent overdose was identified qualitatively and confirmed
using notes in the electronic medical record by S.M. and assistants.
A Shapiro-Wilk test was performed to determine if data distri-
bution was normal for associations between patient characteristics
and each subtype of EPSs or OMDs. When calculating correlation
coefficients, Pearson correlation tests were used for parametric data
and Spearman ρ tests were used for nonparametric data. Bivariate
correlation was performed between baseline characteristics and
the subtype of EPSs or OMDs. χ2 Tests and Fisher exact tests
were used to compare between DRBA and the subtype of EPSs
or OMDs. A P value of <0.05 was considered to be statistically
significant in all tests. All analyses were done using SPSS v28.
RESULTS
A total of 391 billed encounters were obtained using ICD
codes corresponding to DRBA-related EPSs or OMDs diagnoses
(Fig. 1). After manual chart review, 148 patient encounters with
unique DRBA-related EPS or OMD events were included for fur-
ther analysis. The average patient in the study population was fe-
male, middle-aged, and overweight (Table 1). All subtypes of
EPSs or OMDs investigated in this study were well-represented
in the group. Tardive dyskinesia and parkinsonism were the most
commonly experienced subtypes, whereas dystonia and NMS
were the least common.
Most patients were prescribed monotherapy with an oral second-
generation DRBA, such as quetiapine (Table 2). The majority of
doses prescribed were within the normal therapeutic range for main-
tenance treatment of a psychotic disorder, with a median daily ex-
posure of 226.3 mg of chlorpromazine equivalents (CPZEs) and
anticholinergic burden of 2. Dopamine receptor blocking agent
overdose was rare and only associated with EPSs or OMDs in
TABLE 1. Baseline Demographic Characteristics of Patients
Experiencing a Validated DRBA-Related EPSs or OMDs Event
Characteristic Description (N = 148)






Sex Male 50 (33.8%)
Female 98 (66.2%)
BMI category, kg/m2 Mean, 28.9 (range, 16.0–48.8; SD, 6.6)
Underweight (<18.5) 3 (2.0%)
Normal (18.5–25) 39 (26.4%)
Overweight (25–30) 50 (33.8%)
Obese (>30) 56 (37.8%)






*Total > 100%, as some patients experiencedmultiple subtypes of EPSs
or OMDs.
TABLE 2. Dopamine Receptor Blocking Agent
Pharmacotherapy Regimen Characteristics of Patients
Experiencing a Validated DRBA-Related EPS or OMD Event
Characteristic Description (N = 148)













Classification*† First generation 43 (29.1%)
Second generation 125 (84.5%)
Both 22 (14.9%)

























DRBA overdose Yes 7 (4.7%)
No 141 (95.3%)
*Total ≠ 100%, as some patients were taking multiple DRBAs.
†Total ≠ 100%, as complete medication administration history (DRBA
name, dose, and route) was not available for some patients.
IM indicates intramuscular; IV, intravenous; LAI, long-acting inject-
able; PO, oral.
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4.7% of patients. Most patients (73.6%) were prescribed a concur-
rent non-DRBA medication that either caused EPSs or OMDs in-
dependently (12.8%), had the potential to interact with a DRBA
(31.1%), or could ameliorate/mask symptoms of EPSs or OMDs
(81.1%) (Table 3; see Supplementary Appendix 2, Supplemental
Digital Content 2, http://links.lww.com/JCP/A580, for complete list).
A statistically significant correlation was observed between
subtypes of EPSs or OMDs and the patient characteristics of age,
BMI category, and total ACB score (Table 4). Negative correlation
coefficients were observed between age and akathisia (r = −0.365,
P < 0.05) and dystonia (r = −0.269, P < 0.05), meaning that
the likelihood of these subtypes of EPSs increased as age de-
creased. There was a noted positive correlation between TD and age
(r=0.274,P<0.05). Bodymass index category (underweight, normal,
overweight, or obese) was negatively correlated with dystonia
(r = −0.203, P < 0.05), indicating that the likelihood of dystonia
was greater in underweight and normal weight patients as com-
pared with overweight or obese patients in this population. Daily
anticholinergic burden was also negatively correlated with dysto-
nia (r = −0.170, P < 0.05), such that as anticholinergic burden in-
creased, the incidence of dystonia decreased.
Fisher exact test was used to compare subtypes of EPSs or
OMDs and dichotomous variables (female sex, DRBA overdose,
etc) (Table 5). Odds ratios (ORs) greater than 1 indicate an in-
creased likelihood of a certain subtype of EPSs or OMDs occurring
in the presence of a given characteristic or exposure, whereas anOR
of less than 1 indicates a decreased likelihood. Female sex, DRBA
polytherapy, daily CPZE, andDRBAoverdosewere not found to be
significantly associated with any subtype of EPSs or OMDs.
Statistically significant associations were, however, seen with in-
dividual DRBAs and the development of different subtypes of EPSs
or OMDs. Clozapine (n = 9) exposure was highly predictive of NMS
in this population (OR, 8.824; P = 0.004), whereas iloperidone
(n = 10) and lurasidone (n = 9) were associated with an over
4-fold increase in the likelihood of NMS (OR, 4.370; P = 0.044)
and parkinsonism (OR, 4.102; P = 0.046), respectively. First-
generation DRBAs as a class were associated with a nearly 3-fold
greater likelihood of akathisia (OR, 2.897; P = 0.021), likely driven
by haloperidol exposure (OR, 2.790; P = 0.028). Akathisiawas also
more commonly observed in patients who were taking long-acting
injectable (LAI) formulations of a DRBA (OR, 3.580; P = 0.034).
DISCUSSION
This study represents a pilot investigation describing the
characteristics of patients seen within a community hospital sys-
tem that experienced DRBA-related EPSs or OMDs. Descriptive
analysis of the population as a whole revealed that these patients
tended to be middle-aged, overweight females. Most were taking
a single oral second-generation DRBA at a typical maintenance
dose at the time of diagnosis, and overdose on these agents was
not commonly associated with the patient's presentation. These
findings are interesting to consider in the context of published lit-
erature describing a dose-dependent relationship for DRBA-
related EPSs16,20–22,28,33 and linking risk of EPSs to factors such
as dopamine D2 receptor binding affinity
22 and association rate.34
Nevertheless, we know this interdependence to be complex and
variable based on characteristics of the patient population and treat-
ment. For example, aripiprazole demonstrates a dose-dependent
risk of EPSs and other treatment-emergent adverse effects in chil-
dren, but no noted dose-dependency for these effects in adults.35
Regarding treatment differences, the rates of EPSs for certain
second-generation DRBAs such as risperidone and olanzapine
positively correlate with dose,15 whereas others such as clozapine
and quetiapine do not exhibit dose-dependency effects.22
The concept of dopamine blocking potency is important to
consider when accounting for the differences in risk of EPSs or
OMDs observed with each DRBA. First-generation agents such
TABLE 3. Concurrent Use of InteractingMedications in Patients












Agents that could interact












Agents that could ameliorate/mask










TABLE 4. Correlations Coefficients for Associations Between Patient Characteristic and Subtype of EPSs or OMDs
Akathisia Dystonia Parkinsonism TD NMS
Age* −0.365‡ −0.269‡ 0.154 0.274‡ −0.040
BMI category† −0.113 −0.203‡ 0.065 0.107 0.089
Total daily ACB score† −0.054 −0.170‡ 0.064 0.074 0.084
*Pearson correlation test was used to calculate correlation coefficient (parametric data).
†Spearman ρ test was used to calculate correlation coefficient (nonparametric data).
‡Correlation is statistically significant (P < 0.05).
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as haloperidol are believed to have a propensity to cause EPSs
owing to their stronger dopamine blocking effects and lack of se-
rotonin signaling.13,15,20,36 Analysis of the study population did
indeed demonstrate that first-generation agents were associated
with significantly greater odds of developing akathisia, which
is supported by previously published findings.37 First-generation
DRBAs are also associated with an increased risk of NMS be-
cause of their high dopamine binding affinity.38 However, under
the current treatment paradigm, these medications are not used
as commonly as second-generation DRBAs for chronic therapy,
as reflected in the study population. Although the second-generation
class purportedly possesses lower risk of EPSs overall, significant
variability exists between agents.15,16,21,36 Clozapine and quetiapine
have low dopamine receptor occupancy, whereas that of olanzapine
is intermediate, and the binding of risperidone and ziprasidone is
considered high.15,22 This corresponds to the risk of developing
EPSs with exposure to each agent,20,39,40 with the exception of
akathisia, which is thought to be equal across all second-
generation agents.22 Besides this idiosyncrasy with akathisia, it
has not been established if different presentations of EPSs or OMDs
vary in their frequency with exposure to the individual DRBAs.
Analysis of the study population did in fact reveal significant
associations between certain DRBAs and the subtype of EPSs or
OMDs experienced by a patient. Haloperidol was discovered to
confer excess risk for the development of akathisia and lurasidone
for parkinsonism, both results which are supported by clinical trial
data.41,42 The odds of a patient in the study population experiencing
NMS were higher if they were exposed to iloperidone, a finding
which supports the notion that greater dopamine blocking affinity
is a precipitating factor for the development of NMS, as iloperidone
is considered to have high dopamineD2 receptor binding affinity.
43,44
Conversely, the association of clozapine with NMS does not follow
this pattern, as clozapine is a low potency DRBA.45 This observa-
tion may instead reflect the fact that a large percentage of patients
(40%) who experienced NMS while taking clozapine were pre-
scribed multiple DRBA agents, which is a known risk factor for
the development of NMS.25
It is important to consider these findings in the context of the
single patient population in which they occurred. The reported
ORs representing the risk of experiencing different subtypes of
EPSs or OMDs with exposure to various DRBAs, for instance,
are intended to be descriptive and not predictive. A larger or more
statistically meaningful relationship for one DRBA than another
does not imply that one agent confers a comparatively higher risk
for a given outcome, only that in specific population studied, ex-
posure to that agent resulted in a greater risk compared with no
TABLE 5. Odds Ratios for Associations Between Patient Characteristics and Subtype of DRBA-Related EPSs or OMDs
Akathisia Dystonia Parkinsonism TD NMS
Female sex 0.555 1.110 0.580 2.207 0.558
Agent
Aripiprazole 2.989 1.027 0.509 0.874 1.027
Asenapine 9.000 — 1.486 — —
Clozapine 0.509 — 0.833 0.833 8.824*
Haloperidol 2.790* 2.374 0.376 0.376 0.846
Iloperidone 0.449 0.608 0.309 0.309 4.370*
Lurasidone 1.220 — 4.102* 0.833 0.690
Olanzapine 0.181 0.248 0.908 1.583 0.930
Paliperidone 3.111 1.928 0.309 0.721 0.608
Perphenazine 1.420 — 3.057 9.529 —
Quetiapine 0.733 0.811 1.820 0.887 1.400
Risperidone 0.817 0.209 1.263 1.603 0.464
Thiothixene — — — — —
Ziprasidone 0.400 3.714 1.114 0.635 1.278
Classification
First Generation 2.897* 1.873 0.486 0.728 0.681
Second Generation 0.722 0.504 2.242 0.824 1.810
Polytherapy 1.711 0.601 1.098 0.602 1.430
Route of administration
IM route 1.282 2.077 0.567 0.339 2.077
IV route 4.269 2.070 — 0.935 —
LAI route 3.580* 2.775 0.746 0.746 —
PO route 0.990 0.188 2.500 1.478 1.083
Total daily chlorpromazine equivalents, mg
<200 0.987 0.619 1.099 1.291 1.077
200–1000 0.999 1.327 1.010 1.177 0.644
>1000 1.050 1.556 0.679 — 2.849
Overdose 3.317 — 4.364 — 0.952
—, Insufficient number of patients to calculate OR.
*Association is statistically significant (P < 0.05).
IM indicates intramuscular; IV, intravenous.
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exposure. Haloperidol, for example, was found to have a signifi-
cant positive association with akathisia, whereas lurasidone did
not. Nevertheless, in our clinical experience, akathisia tends to be a
relatively more problematic adverse movement reaction with
lurasidone treatment than with haloperidol.
When examining associations between study population char-
acteristics and subtype of EPSs or OMDs, age emerged as another
important patient-related risk factor. Associations of agewith dysto-
nia and TD match those found in the literature.46,47 It appears that
this work is the first to describe a statistically significant relation-
ship between age and the development of akathisia with the use
of DRBAs. To date, prospective cohort studies of community-
dwelling patients with schizophrenia48 and literature reviews ex-
ploring the epidemiology of drug-induced akathisia49,50 have not
been able to draw firm conclusions regarding age as a risk factor
for akathisia. It is possible that including a wider age group of pa-
tients in the present study population (range, 14–96 years old)
allowed for differences in akathisia risk to emerge. This result is
intriguing and may provide additional insight into the mechanism
and management of a poorly understood subtype of EPSs. Further
investigation could assess the interplay of variables such as recep-
tor sensitivity and body composition on the observed relationship
of age and akathisia risk.
Another patient-specific factor found to be significantly as-
sociated with the risk of developing a specific subtype of EPSs was
BMI category. Lower BMI category increased the odds of DRBA-
related dystonia in the study population. Age and BMI category
were not significantly correlated, so this effect was independent of
the increased risk of dystonia seen in younger patients.51 One po-
tential explanation is duration of therapy. Dystonia can occur im-
mediately after administration of a DRBA, compared with weeks
or months of exposure required to develop other subtypes of
EPSs.46 Accordingly, it is less likely that these patients would
have suffered significant weight gain from chronic DRBA use at
the time of developing dystonia. It is also possible that there exists
an interaction between DRBA-induced metabolic syndrome and
the risk of EPSs that has not previously been identified. Assuming
that dystonia, like other subtypes of EPSs, is related to total inci-
dent exposure, perhaps it could be related to BMI by way of alter-
ations in some pharmacokinetic and/or pharmacodynamic factors
related to nutrition, such as protein binding capacity, end organ func-
tion, CYP450 enzyme activity, epigenetic modifications, blood-brain
barrier permeability, or vitamin/mineral status.52–57
It was surprising that the patient characteristic of sex was not
observed to be significantly associated with a subtype of EPSs or
OMDs in the study population, as previous research demonstrated
that dystonia and NMS are more common in males, whereas par-
kinsonism and TD are more common in females.13,41 This unex-
pected outcome may have resulted from the relatively low number
of males (n = 50, 33.8%) represented in the study group. There
was also noted to be a significant correlation between age and
sex in this population, such that males tended to be younger and
females tended to be older. This intrinsic relationship may have in-
fluenced observed associations between age, sex, and subtype of
EPSs or OMDs, and can offer an explanation as to why certain
known risk factors were not detected in the study population.
The lack of an observed interaction with DRBA dosewas also
interesting to note. Daily CPZE was not found to be significantly
associated with any subtype of EPSs or OMDs in the study popula-
tion. The pathogenesis of EPSs is complex and likely results from ac-
tivity atmultiple different receptor subtypes besides simply dopamine
D2. Chlorpromazine equivalent may therefore serve as more of a sur-
rogate marker for EPS or OMD-inducing potential of DRBAs,31
which may explain why a clear association was not detected in the
present study. It is important to note that many patients in this study
were prescribed concurrent anticholinergic medications (33.1%) or
benzodiazepines (38.5%), which can have mitigating effects on mus-
culoskeletal dysfunction and are often used to treat EPSs or OMDs.15
As would be predicted, increasing anticholinergic burden was
found to have a significant negative correlation with the develop-
ment of dystonia in the study population. Overall, the lack of a
dose-dependent effect as measured by number of agents, over-
dose, and daily CPZE suggests that the DRBA itself and specific
characteristics of the patient taking it are more important in deter-
mining the subtype of EPSs or OMDs experienced than the dose.
This retrospective, outcome-driven study has several limita-
tions. First, EPSs are known to occur spontaneously in patients with
psychiatric disorders, independently of drug treatment58 and may
be similar in terms of severity.59 Therewas noway to uniformly dif-
ferentiate disease-related EPSs from drug-related EPSs in this study.
It also failed to account for differences in diagnoses, which is signif-
icant because patients with mood disorders are observed to have
higher rates of DRBA-related EPSs than patients with schizophre-
nia.17,60,61 Furthermore, DRBA route of administration was not
controlled for in this study, which is known to influence the risk
of EPSs. For example, EPSs incidence is believed to be lower for
depot DRBAs than oral.28 In the study population, akathisia was
more commonly observed in patients prescribed LAI formulations
of a DRBA (OR, 3.580;P = 0.034), although this findingwas likely
a function of the specific agents available as LAIs. Of the
11 patients taking LAI DRBAs, 7 were prescribed paliperidone
and 2 were prescribed aripiprazole. These particular LAI agents,
paliperidone (Invega Sustenna [package insert]; Janssen Pharma-
ceuticals, Inc, Titusville, NJ) and aripiprazole (Aristada [package
insert]; Alkermes, Inc, Waltham, MA), are associated with elevated
rates of akathisia in patients taking typical maintenance doses. Fi-
nally, the number of DRBA-related EPS or OMD events observed
in the study population compared with the number of inpatient
encounters during the same time period where DRBAs were ad-
ministered (148/31,461 = 0.5%) was significantly lower than
published prevalence rates of EPSs or OMDs,16,62 which may
limit generalizability of this research.
Understanding the nature of patient-treatment interactions
can be helpful to predict which individuals might be at risk for de-
veloping certain subtypes of EPSs or OMDs related to DRBA
therapy. Future directions for this research could include exploring
additional patient characteristics such as markers of nutritional
status (eg, albumin and vitamin D), as well as searching for risk
factors associated with the development of other DRBA-related
adverse effects (eg, hyperprolactinemia, hyperglycemia, hyperlipid-
emia, sedation, hypotension, anticholinergic, and QT interval pro-
longation). Ultimately, this information can assist clinicians with
identifying at-risk patients, setting expectations to anticipate proba-
ble adverse effects, and using early intervention strategies aimed to
improve adherence and overall outcomes with DRBA therapy.
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